FDA Launches Elsa 4.0 and HALO Platform to Modernize Internal AI Capabilities

The U.S. Food and Drug Administration has launched two new internal AI platforms — Elsa 4.0 and the HALO (Health AI and Learning Operations) system — as part of a broader effort to modernize the agency's data infrastructure and accelerate regulatory science. The platforms are designed to improve how the FDA processes scientific evidence, conducts drug and device reviews, and manages its internal knowledge base.^[1]

Elsa 4.0 is an upgraded version of the FDA's internal AI assistant, which allows agency staff to query regulatory documents, scientific literature, and submission databases using natural language. The new version incorporates a larger underlying language model, improved citation accuracy, and new capabilities for analyzing structured data from clinical trial submissions. The system is designed to help reviewers quickly surface relevant precedent, identify gaps in submission packages, and draft sections of review documents.^[1]

The HALO Platform

HALO is a broader data integration and AI governance platform that consolidates the FDA's previously fragmented data systems into a unified infrastructure. The platform provides a standardized environment for developing, validating, and deploying AI tools across the agency's centers, including the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Devices and Radiological Health (CDRH). HALO also includes governance tools for tracking AI model performance, managing data access permissions, and auditing AI-assisted decisions.^[2]

Regulatory Implications

The FDA's investment in internal AI capabilities has direct implications for the health AI industry. As the agency becomes more sophisticated in its use of AI for internal review processes, it is also developing more nuanced frameworks for evaluating AI-based medical devices and software. The agency's experience with AI tools internally is expected to inform its guidance on issues including model transparency, post-market surveillance, and the use of real-world evidence in AI device submissions.^[3]

References

1. FDA. "FDA Launches Elsa 4.0 and HALO Platform." May 9, 2026. https://www.fda.gov/news-events/press-announcements
2. FDA. "Artificial Intelligence and Machine Learning in Software as a Medical Device." 2026. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device
3. STAT News. "FDA's new AI tools could reshape how the agency reviews drugs and devices." May 10, 2026. https://www.statnews.com/2026/05/10/fda-ai-tools-elsa-halo-drug-device-review/